195 filings
8-K
AXSM
Axsome Therapeutics Inc
6 May 24
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
7:05am
8-K
AXSM
Axsome Therapeutics Inc
1 Apr 24
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
8:27am
8-K
AXSM
Axsome Therapeutics Inc
25 Mar 24
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
9:06am
8-K
AXSM
Axsome Therapeutics Inc
25 Mar 24
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
9:02am
8-K
AXSM
Axsome Therapeutics Inc
19 Mar 24
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
7:06am
8-K
kh3syp li6gm4v6tqb
20 Feb 24
Corporate Presentation February 2024
4:30pm
8-K
8nfxn g1fcxe
20 Feb 24
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:05am
8-K
8mlqbh98beg m8
8 Jan 24
Corporate Presentation January 2024
7:10am
8-K
dpaqdeomo3pwnwpjkf9
4 Jan 24
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
7:11am
8-K
v63a9
7 Dec 23
Other Events
4:05pm
8-K
e0yz42tni4tpt
6 Nov 23
Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:05am
8-K
edi1i
11 Oct 23
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors
5:03pm
8-K
np70i hirvcsh5shnkg
15 Aug 23
Corporate Presentation August 2023
7:45am
8-K
kt1y7
7 Aug 23
Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:02pm
8-K
c3vnthsmwlm49xg oth
4 Aug 23
Other Events
4:49pm
8-K
2ry5 0sv60
7 Jul 23
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
8:21am
8-K
tm60y xfkc48j6cd3
30 Jun 23
Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock
4:05pm
8-K
y7yivp4o893c3m53
28 Jun 23
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
7:50pm
8-K
i5mqgfb9
26 Jun 23
Changes in Registrant's Certifying Accountant
5:01pm
8-K
dcij9td7
13 Jun 23
Financial Statements and Exhibits
5:22pm